Novartis Secures Ophthalmic Diversity With Final Alcon Buyout
Executive Summary
Novartis' new eye care division, created by folding together Alcon, CIBA Vision and some of the Swiss pharma's own ophthalmic therapies, will control more than 70 percent of the global eye care market at its inception. And it has a range of pipeline projects in the works to support that hegemony going forward
You may also be interested in...
The Sound Of Opportunity: Novartis Inks Deal With GenVec For Hearing Loss R&D
GenVec's gene-based program targets a hearing loss world ruled by devices.
The Sound Of Opportunity: Novartis Inks Deal With GenVec For Hearing Loss R&D
GenVec's gene-based program targets a hearing loss world ruled by devices.
Novartis Seeks Eye Care Leadership With Full, $50 Billion Alcon Takeover
Novartis pays $28.1 billion for a further 52 percent stake in Alcon, seeking full control with a further offer to buy out minority shareholders.